La Rosa (NASDAQ:LRHC – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($5.44) EPS for the quarter, Zacks reports.
La Rosa Price Performance
LRHC traded down $0.45 during trading on Wednesday, reaching $2.15. The company’s stock had a trading volume of 126,189 shares, compared to its average volume of 149,979. The company has a market cap of $2.63 million, a price-to-earnings ratio of 0.00 and a beta of 1.79. The firm has a fifty day simple moving average of $6.13 and a two-hundred day simple moving average of $7.68. La Rosa has a 1 year low of $2.12 and a 1 year high of $95.20. The company has a quick ratio of 2.44, a current ratio of 2.44 and a debt-to-equity ratio of 1.14.
Hedge Funds Weigh In On La Rosa
A hedge fund recently bought a new stake in La Rosa stock. Marex Group plc bought a new stake in La Rosa Holdings Corp. (NASDAQ:LRHC – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 358,600 shares of the company’s stock, valued at approximately $47,000. Marex Group plc owned approximately 49.12% of La Rosa as of its most recent SEC filing. 7.63% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Read Our Latest Stock Analysis on La Rosa
About La Rosa
La Rosa Holdings Corp., through its subsidiaries, operates primarily in the residential real estate market in the United States. The company operates through five segments: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, and Real Estate Brokerage Services (Commercial).
Further Reading
- Five stocks we like better than La Rosa
- How to Invest in Biotech Stocks
- HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
- Are Penny Stocks a Good Fit for Your Portfolio?
- End the Year Strong With These 3 Comeback Champions
- The Role Economic Reports Play in a Successful Investment Strategy
- Down 45% Year-to-Date, Novo Nordisk Ignites a Price War
Receive News & Ratings for La Rosa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Rosa and related companies with MarketBeat.com's FREE daily email newsletter.
